bioRxiv Science⌕ Search

Biology subjects

Canaday, N. M.

Publications and source records attributed to Canaday, N. M..

2 recordsLinked to original sources

Vaccination of pregnant mares with mRNA encoding a GPI-anchored form of the virulence-associated protein A of Rhodococcus equi induces strong IgG responses that are transferred to their foals

The bacterium Rhodococcus equi is a common cause of severe pneumonia in foals worldwide. Foals are exposed to R. equi from birth and are most susceptible in the first weeks of life. In North America, control measures are limited to transfusion to newborn foals of hyperimmune plasma whose potency is assessed by surpassing a threshold of IgG against the virulence-associated protein A (VapA) of R. equi. Here we report results of vaccination of pregnant mares with mRNA encoding a GPI-anchored virulence-associated protein A (VapA) of R. equi induced VapA-specific IgG subisotypes transferred to their foals during the 63-day period after birth. Pregnant mares were randomly assigned to receive either VapA mRNA vaccine (n=10) at 8 and 10 months of gestation or no vaccine (n=10). Serum was collected from mares at 8 months of gestation (before vaccination for immunized mares) and {approx}24 hours after foaling and from foals at ages 1, 35, and 63 days. Mean relative concentrations of were low before immunization in all mares and did not change over time in unvaccinated mares; however, mean relative concentrations of anti-VapA IgG1, IgG4/7, and IgG3/5 of mares were significantly increased after VapA mRNA immunization and strongly correlated with the corresponding concentrations in their foals sera at age {approx}24 hours. Concentrations of anti-VapA IgGs remained increased in foals of vaccinated mares compared with control foals for at least 35 days.

immunology↗

Antibody Activities in Hyperimmune Plasma Against the Rhodococcus equi Virulence -Associated Protein A or Poly-N-Acetyl Glucosamine are Associated with Protection of Foals Against Rhodococcal Pneumonia

The efficacy of transfusion with hyperimmune plasma (HIP) for preventing pneumonia caused by Rhodococcus equi remains ill-defined. Quarter Horse foals at 2 large breeding farms were randomly assigned to be transfused with 2 L of HIP from adult donors hyperimmunized either with R. equi (RE HIP) or a conjugate vaccine eliciting antibody to the surface polysaccharide {beta}-1[->]6-poly-N-acetyl glucosamine (PNAG HIP) within 24 hours of birth. Antibody activities against PNAG and the rhodococcal virulence-associated protein A (VapA), and to deposition of complement component 1q (C1q) onto PNAG were determined by ELISA, and then associated with either clinical pneumonia at Farm A (n=119) or subclinical pneumonia at Farm B (n=114). Data were analyzed using multivariable logistic regression. Among RE HIP-transfused foals, the odds of pneumonia were approximately 6-fold higher (P = 0.0005) among foals with VapA antibody activity [≤] the population median. Among PNAG HIP-transfused foals, the odds of pneumonia were approximately 3-fold (P = 0.0347) and 11-fold (P = 0.0034) higher for foals with antibody activities [≤] the population median for PNAG or C1q deposition, respectively. Results indicated that levels of activity of antibodies against R. equi antigens are correlates of protection against both subclinical and clinical R. equi pneumonia in field settings. Among PNAG HIP-transfused foals, activity of antibodies with C1q deposition (an indicator of functional antibodies) were a stronger predictor of protection than was PNAG antibody activity alone. Collectively, these findings suggest that the amount and activity of antibodies in HIP (i.e., plasma volume and/or antibody activity) is positively associated with protection against R. equi pneumonia in foals.

immunology↗